Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-05-15

FDA Approved: TRUVADA — Supplemental Application (Gilead Sciences, Inc)

View source ↗

Summary

The FDA approved a supplemental application for TRUVADA (emtricitabine and tenofovir disoproxil fumarate) submitted by Gilead Sciences, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)

Snippet

SUPPL AP for TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)